Hairy cell leukemia

Related records

Broader conditions (29)

• Acute disease
• Acute leukemia
• Acute lymphoblastic leukemia
• B-cell chronic lymphocytic leukemia
• B-cell neoplasm
• B-cell non-Hodgkin lymphoma
• Cancer or benign tumor
• Chronic leukemia
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Hematologic disorder
• Hematopoietic and lymphoid cell neoplasm
• Hematopoietic and lymphoid system neoplasm
• Human disease
• Immune system disorder
• Indolent B-cell non-Hodgkin lymphoma
• Leukemia
• Leukocyte disorder
• Lymphoid hemopathy

Narrower conditions (4)

• Hairy cell leukemia variant
• Intrapelvic lymph node leukemic reticuloendotheliosis
• Refractory hairy cell leukemia
• Splenic manifestation of hairy cell leukemia

Trials (239)

• 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
• 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
• A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
• A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia
• A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
• A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
• A Standardized Nursing Intervention Protocol for HCT Patients
• A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
• A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
• A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
• Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
• Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
• Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Approved drugs (4)

• Cladribine
• Interferon alfa-2B
• Moxetumomab pasudotox
• Pentostatin

Drugs in development (26)

• Acetaminophen Phase 2
• Aspirin Phase 1
• Bendamustine Phase 2
• Binimetinib Phase 2
• BL22 Phase 2
• Brexucabtagene autoleucel Phase 2
• Busulfan Phase 2
• Cyclophosphamide Phase 2
• Dabrafenib Phase 2
• Dexamethasone Phase 1
• Diphenhydramine Phase 2
• Encorafenib Phase 2
• Epinephrine Phase 2
• Famotidine Phase 1
• Fludarabine Phase 2
• Interferon alfa-2A Phase 2
• LMB-2 Phase 2
• Obinutuzumab Phase 2
• Peginterferon alfa-2A Phase 2
• Plixorafenib Phase 1